Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing
Authors:
- Valeria BariliVBValeria Barili
- Enrico AmbrosiniEAEnrico Ambrosini
- Beatrice BortesiBBBeatrice Bortesi
- Roberta MinariRMRoberta Minari
- Erika De SensiESErika De Sensi
- Ilenia Rita CannizzaroICIlenia Rita Cannizzaro
- Antonietta TaianiATAntonietta Taiani
- Maria MichiaraMMMaria Michiara
- Angelica SikokisASAngelica Sikokis
- Daniela BoggianiDBDaniela Boggiani
- Chiara TommasiChiara Tommasi
- Olga SerraOSOlga Serra
Open Access
Abstract
Germline variants occurring in BRCA1 and BRCA2 give rise to hereditary breast and ovarian cancer (HBOC) syndrome, predisposing to breast, ovarian, fallopian tube, and peritoneal cancers marked by elevated incidences of genomic aberrations that correspond to poor prognoses. These genes are in fact involved in genetic integrity, particularly in the process of homologous recombination (HR) DNA repair, a high-fidelity repair system for mending DNA double-strand breaks. In addition to its implication in HBOC pathogenesis, the impairment of HR has become a prime target for therapeutic intervention utilizing poly (ADP-ribose) polymerase (PARP) inhibitors. In the present review, we introduce the molecular roles of HR orchestrated by BRCA1 and BRCA2 within the framework of sensitivity to PARP inhibitors. We examine the genetic architecture underneath breast and ovarian cancer ranging from high- and mid- to low-penetrant predisposing genes and taking into account both germline and somatic variations. Finally, we consider higher levels of complexity of the genomic landscape such as polygenic risk scores and other approaches aiming to optimize therapeutic and preventive strategies for breast and ovarian cancer.Keywords
Funding Information
- Fondazione Emma ed Ernesto Rulfo per la Genetica Medica (MUR_DM737_2022)
- BANDO DI ATENEO PER LA RICERCA 2022 (MUR_DM737_2022)
- University of Parma (MUR_DM737_2022)
This publication has 170 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- A guide for functional analysis ofBRCA1variants of uncertain significanceHuman Mutation, 2012
- ENIGMA-Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genesHuman Mutation, 2011
- Early onset HER2‐positive breast cancer is associated with germline TP53 mutationsCancer, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- Common variations in BARD1 influence susceptibility to high-risk neuroblastomaNature Genetics, 2009
- Proportionally more deleterious genetic variation in European than in African populationsNature, 2008
- Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerJAMA, 2007
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Identification of a RING protein that can interact in vivo with the BRCA1 gene productNature Genetics, 1996